Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Preclinical evaluation of macrophage reprogramming in treatment of CTCL

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMadeline WilliamsCPCarla Portocarrero

Discussion

Loading...

Member takes

Overview

Preclinical study shows tumor-associated macrophages targeting could inhibit growth in cutaneous T-cell lymphoma, implying new treatment avenues.

Key Points

  • This research aims to evaluate the role of macrophage reprogramming in the treatment of cutaneous T-cell lymphoma.
  • Utilized scRNA-seq to assess macrophages in CTCL lesional skin biopsies.
  • Conducted assessments in CTCL mouse models and cancer cell-macrophage co-cultures.
  • Implemented treatments with a CD206 binding peptide, RP-832c, and TLR4 inhibitor, TAK-242.
  • CTCL-associated macrophages exhibited a tumor-promoting phenotype with increased CD206 and TLR4 expression.
  • Treatment with RP-832c and TAK-242 shifted macrophage phenotype from tumor-promoting to tumor-suppressive.
  • Inhibition of TLR4 resulted in diminished CTCL tumor growth in mouse models.

Cite This Study

Williams et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db5fhttps://doi.org/10.1182/blood-2025-5347
View Full Paper
Ask AI
Bookmark
Share